Mangalam Drugs & Organics last traded at ₹31.87 (2026-10-13). Over the past month the stock moved -8.5%, three months the stock moved +10.1%, year the stock moved -58.0%. Its closing range over 52 weeks is ₹23.84 – ₹70.38, with the latest close 54.7% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]
Business Overview:[1] MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.
In the latest quarter (Jun 2026), Mangalam Drugs & Organics reported sales of ₹57.12 crore (-0.2%) and net profit of ₹-7.55 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 57.12 | 0.90 | 1.58 | -7.55 | -4.77 |
| Mar 2026 | 67.29 | -5.36 | -7.97 | -13.06 | -8.25 |
| Dec 2025 | 58.38 | -1.58 | -2.71 | -9.78 | -6.18 |
| Sep 2025 | 49.54 | -2.83 | -5.71 | -7.25 | -4.58 |
| Jun 2025 | 57.21 | -4.65 | -8.13 | -13.73 | -8.67 |
| Mar 2025 | 72.78 | 9.90 | 13.60 | 0.15 | 0.09 |
| Dec 2024 | 88.71 | 8.77 | 9.89 | 1.40 | 0.88 |
| Sep 2024 | 79.94 | 8.69 | 10.87 | 2.69 | 1.70 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -2.0% | -8.9% | -28.8% | -25.2% | -38.0% | -34.2% | -7.5% | -0.2% |
| Operating profit growth | +296.8% | +25.6% | -15.4% | -156.8% | -132.6% | -118.0% | -154.1% | – |
| Net profit growth | – | +180.0% | -95.8% | -612.3% | -369.5% | -798.6% | -8806.7% | – |
| EPS growth | – | +175.0% | -96.0% | -613.0% | -369.4% | -802.3% | -9266.7% | – |
| OPM % | 10.9% | 9.9% | 13.6% | -8.1% | -5.7% | -2.7% | -8.0% | 1.6% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Mangalam Drugs & Organics reported sales of ₹232.00 crore (-27.0%) and net profit of ₹-44.00 crore (-728.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 232.00 | -15.00 | -6.00 | -44.00 | -27.68 |
| Mar 2025 | 318.00 | 36.00 | 11.00 | 7.00 | 4.25 |
| Mar 2024 | 369.00 | 17.00 | 5.00 | -9.00 | -5.73 |
| Mar 2023 | 372.00 | 26.00 | 7.00 | 1.00 | 0.80 |
| Mar 2022 | 451.00 | 49.00 | 11.00 | 20.00 | 12.42 |
| Mar 2021 | 380.00 | 53.00 | 14.00 | 28.00 | 17.67 |
| Mar 2020 | 282.00 | 24.00 | 8.00 | 8.00 | 5.21 |
| Mar 2019 | 228.00 | 10.00 | 4.00 | -8.00 | -5.07 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -15.2% | +23.7% | +34.8% | +18.7% | -17.5% | -0.8% | -13.8% | -27.0% |
| Operating profit growth | -78.7% | +140.0% | +120.8% | -7.5% | -46.9% | -34.6% | +111.8% | -141.7% |
| Net profit growth | -140.0% | – | +250.0% | -28.6% | -95.0% | -1000.0% | – | -728.6% |
| EPS growth | -140.3% | – | +239.2% | -29.7% | -93.6% | -816.3% | – | -751.3% |
| OPM % | 4.0% | 8.0% | 14.0% | 11.0% | 7.0% | 5.0% | 11.0% | -6.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Mangalam Drugs & Organics.
Get Free AI Stock Analysis FREE →Mangalam Worldwide records highest-ever monthly export turnover - scanx.trade
Mangalam Worldwide records highest-ever monthly export turnover - scanx.trade
Mangalam Global Enterprise consolidated net profit rises 31.10% in the June 2026 quarter - Business Standard
Mangalam Organics reports Profit after tax of Rs 53.23 Mln, in the June 2026 quarter
Mangalam Worldwide Q1 Profit Rises 19%
Mangalam Worldwide Q1 Profit Rises 19%
Mangalam Worldwide consolidated net profit rises 17.69% in the June 2026 quarter - Business Standard
Hindalco evaluating Rs 50,000 crore investments, says chairman Kumar Mangalam Birla - The Economic Times
Mangalam Global Enterprise soars on inaugurating three new stores in Mumbai
Mangalam Worldwide shareholders approve share split from ₹10 to ₹1 - scanx.trade
Mangalam Drugs & Organics shares were last quoted at ₹31.87 (+2.6% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Mangalam Drugs & Organics has a price-to-earnings (P/E) ratio of -1.34 and a price-to-book (P/B) ratio of 0.53. The industry P/E is 53.33.
The 52-week high of Mangalam Drugs & Organics is ₹77.90 and the 52-week low is ₹22.70.
The market capitalisation of Mangalam Drugs & Organics is about ₹50.49 crore.
In the latest quarter (Jun 2026), Mangalam Drugs & Organics reported sales of ₹57.12 crore (-0.2%) and net profit of ₹-7.55 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Mangalam Drugs & Organics has a 3-year ROE of -11.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 35.65% of Mangalam Drugs & Organics.
Mangalam Drugs & Organics belongs to the Pharmaceuticals & Drugs sector.